Antimicrobial Agents and Chemotherapy · 2013 · 75 citations · 21 references
MedicineInternal MedicinePharmacologyBioavailabilityDiabetologyPharmacokinetic VariabilityDiabetes MellitusPulmonary TuberculosisTuberculosis CareTuberculosis EpidemiologyTuberculosis PharmacotherapyTuberculosis PreventionActive Pulmonary Tuberculosis
Plasma isoniazid and rifampin concentrations, but not pyrazinamide and ethambutol concentrations, were decreased by about 50% (P < 0.05) in diabetic pulmonary tuberculosis patients. The prevalences of subnormal plasma isoniazid, rifampin, pyrazinamide, and ethambutol concentrations were 49% or 100% (P < 0.01), 66% or 100% (P < 0.05), 30% or 50% (P = 0.198), and 32% or 21% (P = 0.742) in nondiabetic or diabetic tuberculosis patients, respectively. These data show that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients.
21
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Amina Jindani, V R Aber, Eric Edwards et al. · PubMed · 1980 · 498 citations
Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients.
Rupak Singla, N Al-Sharif, M O Ai-Sayegh et al. · PubMed · 2006 · 206 citations